$CKX
CKX LANDS, INC.

2023 Q2 Form 10-Q Financial Statement

#000143774923012980 Filed on May 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $370.4K $165.8K $181.9K
YoY Change 19.39% -8.88% 17.46%
Cost Of Revenue $13.22K $10.20K $11.10K
YoY Change -24.76% -8.11% 20.92%
Gross Profit $357.2K $155.6K $170.8K
YoY Change 22.05% -8.93% 17.24%
Gross Profit Margin 96.43% 93.85% 93.9%
Selling, General & Admin $254.0K $647.3K $172.4K
YoY Change -57.48% 275.57% 67.2%
% of Gross Profit 71.11% 416.11% 100.9%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.065K $1.065K $507.00
YoY Change 55.93% 110.06% 0.0%
% of Gross Profit 0.3% 0.68% 0.3%
Operating Expenses $255.1K $648.4K $172.9K
YoY Change -57.35% 275.08% 66.87%
Operating Profit $102.1K -$342.8K -$2.037K
YoY Change -133.44% 16729.11% -100.45%
Interest Expense $35.54K $25.96K $2.610K
YoY Change 823.12% 894.64% -44.11%
% of Operating Profit 34.81%
Other Income/Expense, Net $0.00 $0.00 $3.020K
YoY Change -100.0% -100.0%
Pretax Income $137.6K -$316.9K $3.593K
YoY Change -145.69% -8918.56% -99.21%
Income Tax $34.41K -$79.21K -$1.147K
% Of Pretax Income 25.0% -31.92%
Net Earnings $103.2K -$237.6K $4.740K
YoY Change -137.31% -5113.48% -98.89%
Net Earnings / Revenue 27.87% -143.36% 2.61%
Basic Earnings Per Share $0.05 -$0.12 $0.00
Diluted Earnings Per Share $0.05 -$0.12 $2.440K
COMMON SHARES
Basic Shares Outstanding 1.974M 1.974M 1.942M
Diluted Shares Outstanding 2.285M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.386M $8.205M $7.860M
YoY Change 10.17% 4.4% 7.11%
Cash & Equivalents $8.386M $7.190M $7.357M
Short-Term Investments $0.00 $1.015M $502.4K
Other Short-Term Assets $120.6K $131.0K $94.05K
YoY Change -15.87% 39.26% -31.47%
Inventory
Prepaid Expenses
Receivables $83.04K $77.41K $48.18K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $8.590M $8.414M $8.002M
YoY Change 8.7% 5.15% 5.7%
LONG-TERM ASSETS
Property, Plant & Equipment $9.098M $9.096M $9.060M
YoY Change 0.15% 0.4% -0.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $344.9K $379.3K
YoY Change
Total Long-Term Assets $9.443M $9.475M $9.060M
YoY Change 3.95% 4.58% -0.72%
TOTAL ASSETS
Total Short-Term Assets $8.590M $8.414M $8.002M
Total Long-Term Assets $9.443M $9.475M $9.060M
Total Assets $18.03M $17.89M $17.06M
YoY Change 6.16% 4.85% 2.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $22.52K $30.94K $115.1K
YoY Change -70.27% -73.13% 18.58%
Accrued Expenses
YoY Change
Deferred Revenue $93.55K $148.7K $148.2K
YoY Change -11.87% 0.35% -14.16%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $116.1K $179.6K $263.3K
YoY Change -36.19% -31.78% -10.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $116.1K $179.6K $263.3K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $116.1K $179.6K $451.0K
YoY Change -68.59% -60.17% -6.6%
SHAREHOLDERS EQUITY
Retained Earnings $15.09M $14.99M $16.55M
YoY Change -7.25% -9.43% 2.46%
Common Stock $59.34K $59.34K $59.34K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.92M $17.71M $16.61M
YoY Change
Total Liabilities & Shareholders Equity $18.03M $17.89M $17.06M
YoY Change 6.16% 4.85% 2.19%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $103.2K -$237.6K $4.740K
YoY Change -137.31% -5113.48% -98.89%
Depreciation, Depletion And Amortization $1.065K $1.065K $507.00
YoY Change 55.93% 110.06% 0.0%
Cash From Operating Activities $194.6K -$90.39K -$48.13K
YoY Change -313.47% 87.82% -68.12%
INVESTING ACTIVITIES
Capital Expenditures $3.380K $17.36K -$4.510K
YoY Change -113.63% -484.92% -68.04%
Acquisitions
YoY Change
Other Investing Activities $1.005M $150.0K -$40.00
YoY Change -201022.0% -375075.0%
Cash From Investing Activities $1.001M $132.6K -$4.542K
YoY Change -4057.43% -3020.17% -100.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities 194.6K -$90.39K -$48.13K
Cash From Investing Activities 1.001M $132.6K -$4.542K
Cash From Financing Activities 0.000
Net Change In Cash 1.196M $42.24K -$52.67K
YoY Change -582.59% -180.2% -114.15%
FREE CASH FLOW
Cash From Operating Activities $194.6K -$90.39K -$48.13K
Capital Expenditures $3.380K $17.36K -$4.510K
Free Cash Flow $191.2K -$107.8K -$43.62K
YoY Change -388.13% 147.04% -68.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 pure
CY2022Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0 usd
CY2023Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0 usd
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2022Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
CY2023Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
CY2023Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
37626 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
148700 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
179637 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1988701
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1988701
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1974427
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1974427
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
59335 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
59335 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2835007 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2308537 usd
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
10166
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
10166
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000352955
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 pure
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
176592 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
176592 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
14991495 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
15229134 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
17709245 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17420414 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17888882 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17687590 usd
CY2023Q1 us-gaap Revenues
Revenues
165762 usd
CY2022Q1 us-gaap Revenues
Revenues
181918 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
647303 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
172349 usd
CY2023Q1 us-gaap Depreciation
Depreciation
1065 usd
CY2022Q1 us-gaap Depreciation
Depreciation
507 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
149992 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
508571 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
183955 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-342809 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2037 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
25958 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2607 usd
CY2023Q1 ckx Miscellaneous Income
MiscellaneousIncome
0 usd
CY2022Q1 ckx Miscellaneous Income
MiscellaneousIncome
3023 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-316851 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3593 usd
CY2023Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-1147 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-79212 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-79212 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1147 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-237639 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
4740 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1974427
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1942495
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17420414 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
526470 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-237639 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
17709245 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16606187 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
4740 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
16610927 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
4740 usd
CY2023Q1 us-gaap Depreciation
Depreciation
1065 usd
CY2022Q1 us-gaap Depreciation
Depreciation
507 usd
CY2023Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-79212 usd
CY2022Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
0 usd
CY2023Q1 us-gaap Depletion
Depletion
0 usd
CY2022Q1 us-gaap Depletion
Depletion
138 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
149992 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
-0 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
10283 usd
CY2022Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-504 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
526470 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
CY2023Q1 us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
53261 usd
CY2022Q1 us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
56088 usd
CY2023Q1 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-87539 usd
CY2022Q1 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
2072 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90391 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48127 usd
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
-0 usd
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
37 usd
CY2023Q1 ckx Payments Of Reforesting Timber Costs
PaymentsOfReforestingTimberCosts
17358 usd
CY2022Q1 ckx Payments Of Reforesting Timber Costs
PaymentsOfReforestingTimberCosts
4505 usd
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
149992 usd
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
132634 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4542 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42243 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52669 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7148207 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7409873 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7190450 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7357204 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<i>Concentration of Credit Risk</i>The Company maintains its cash balances in seven financial institutions. At times, cash balances may exceed the Federal Deposit Insurance Corporation’s insured limit of $250,000. The Company has not experienced any losses in such accounts and management believes the Company is not exposed to any significant credit risk on its cash balances.
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
310794
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9184506 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9167148 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
88601 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
87536 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9095905 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9079612 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
149992 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
0 usd
CY2023Q1 us-gaap Depreciation
Depreciation
1065 usd
CY2022Q1 us-gaap Depreciation
Depreciation
507 usd
CY2023Q1 us-gaap Depletion
Depletion
0 usd
CY2022Q1 us-gaap Depletion
Depletion
138 usd
CY2022 ckx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue
3374002 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
538995 usd
CY2022 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
14274
CY2022 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
46206

Files In Submission

Name View Source Status
0001437749-23-012980-index-headers.html Edgar Link pending
0001437749-23-012980-index.html Edgar Link pending
0001437749-23-012980.txt Edgar Link pending
0001437749-23-012980-xbrl.zip Edgar Link pending
ckx-20230331.xsd Edgar Link pending
ckx20230331_10q.htm Edgar Link pending
ex_512607.htm Edgar Link pending
ex_512608.htm Edgar Link pending
ex_512609.htm Edgar Link pending
ex_512610.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
ckx-20230331_cal.xml Edgar Link unprocessable
ckx-20230331_pre.xml Edgar Link unprocessable
ckx-20230331_def.xml Edgar Link unprocessable
ckx-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ckx20230331_10q_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending